Alivus Life Sciences liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022

4.37×	4.37×	3.67×	4.60×
2.85×	2.85×	2.47×	3.25×
1,012	301	284	512
2,301	1,477	1,346	1,381

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB AARTIDRUGS AKUMS AGARWALEYE APLLTD ADVENZYMES AARTIPHARM CORONA

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	Last 12M 30/09/2026
Current Ratio	4.60	3.67	4.37	4.37
Quick Ratio	3.25	2.47	2.85	2.85
Cash, Equiv & ST Investments	512.2	283.8	301.4	1,011.6
Working Capital	1,380.6	1,345.9	1,477.2	2,301.1

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.